We are live on !
Find out more
Longview Partners Portfolio holdings
AUM
$6.16B
Turnover
15.38%
1-Year Est. Return
3.55%
Longview Partners is a specialist global equity manager that holds a concentrated portfolio of world stocks, using the same philosophy since it started in 2001. It looks for high-quality businesses that can build value steadily over time, wants a margin of safety on price, and relies on picking individual stocks rather than steering the overall portfolio. Its clients are institutions, and Northill Capital is its majority shareholder.
This Fund
S&P 500
This Quarter Est. Return
+5.96%
1 Year Est. Return
+3.55%
3 Year Est. Return
+35.76%
5 Year Est. Return
+55.83%
10 Year Est. Return
+255.17%
AUM
$19.1B
AUM Growth
+$587M
(+3.2%)
Cap. Flow
-$321M
Cap. Flow % of AUM
Cap. Flow %
-1.68%
Top 10 Holdings %
Top 10 Hldgs %
54.55%
Holding
25
New
–
Increased
21
Reduced
1
Closed
3
Avg Time Held
3.1
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$86.9M |
| 2 |
Willis Towers Watson
WTW
|
+$74M |
| 3 |
HCA Healthcare
HCA
|
+$71.3M |
| 4 |
Wells Fargo
WFC
|
+$62.3M |
| 5 |
Zimmer Biomet
ZBH
|
+$60.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aptiv
APTV
|
+$548M |
| 2 |
Progressive
PGR
|
+$296M |
| 3 |
Pediatrix Medical
MD
|
+$107M |
| 4 |
American Express
AXP
|
+$93.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.68% |
| 2 | Financials | 24.54% |
| 3 | Industrials | 19.86% |
| 4 | Technology | 14.95% |
| 5 | Consumer Staples | 5.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
W.W. Grainger
GWW
$69.6B
| $1.22B | 6.38% |
5,157,790
+156,313
| +3% | +$32.3M |
2015 Q4
8 quarters
|
|
2
Parker-Hannifin
PH
$123B
| $1.09B | 5.68% |
5,437,440
+23,982
| +0.4% | +$4.46M |
2015 Q2
10 quarters
|
|
3
Dollar General
DG
$30.3B
| $1.06B | 5.56% |
11,417,858
+96,198
| +0.8% | +$8.27M |
2017 Q2
2 quarters
|
|
|
4
HCA Healthcare
HCA
$106B
| $1.06B | 5.53% |
12,022,516
+887,361
| +8% | +$71.3M |
2013 Q3
17 quarters
|
|
|
5
Wells Fargo
WFC
$258B
| $1.05B | 5.48% |
17,250,127
+1,103,390
| +7% | +$62.3M |
2013 Q2
18 quarters
|
|
6
UnitedHealth
UNH
$361B
| $1.05B | 5.48% |
4,744,455
+19,610
| +0.4% | +$4.16M |
2014 Q1
15 quarters
|
|
7
Emerson Electric
EMR
$93.2B
| $998M | 5.23% |
14,322,835
+564,510
| +4% | +$36.6M |
2015 Q1
11 quarters
|
|
8
Aon
AON
$71.4B
| $969M | 5.08% |
7,234,657
+233,280
| +3% | +$33.2M |
2013 Q2
18 quarters
|
|
|
9
Zimmer Biomet
ZBH
$20.3B
| $969M | 5.07% |
8,268,642
+536,757
| +7% | +$60.7M |
2015 Q3
9 quarters
|
|
10
Fidelity National Information Services
FIS
$15.6B
| $968M | 5.07% |
10,286,362
+260,420
| +3% | +$24.5M |
2013 Q2
18 quarters
|
|
11
Bank of New York Mellon
BNY
$103B
| $952M | 4.98% |
17,675,284
+293,300
| +2% | +$15.6M |
2013 Q2
18 quarters
|
|
12
Pfizer
PFE
$168B
| $936M | 4.9% |
27,250,487
+1,564,853
| +6% | +$53.4M |
2013 Q2
18 quarters
|
|
|
13
Oracle
ORCL
$400B
| $936M | 4.9% |
19,801,511
+1,770,940
| +10% | +$86.9M |
2013 Q2
18 quarters
|
|
14
IQVIA
IQV
$45.2B
| $928M | 4.86% |
9,474,444
+256,217
| +3% | +$26.1M |
2016 Q4
4 quarters
|
|
|
15
Willis Towers Watson
WTW
$30.8B
| $926M | 4.85% |
6,146,219
+468,525
| +8% | +$74M |
2016 Q2
6 quarters
|
|
16
Thermo Fisher Scientific
TMO
$266B
| $926M | 4.85% |
4,876,890
+311,977
| +7% | +$59.8M |
2015 Q3
9 quarters
|
|
17
State Street
STT
$47.4B
| $794M | 4.16% |
8,131,523
+68,797
| +0.9% | +$6.58M |
2017 Q1
3 quarters
|
|
18
Fiserv Inc
FISV
$34B
| $714M | 3.74% |
10,897,338
+114,300
| +1% | +$7.38M |
2013 Q2
18 quarters
|
|
|
TMX
19
DELISTED
Terminix Global Holdings, Inc.
TMX
| $491M | 2.57% |
14,285,175
+115,140
| +0.8% | +$3.71M |
2016 Q2
6 quarters
|
|
20
Omnicom Group
OMC
$24.4B
| $463M | 2.42% |
6,355,879
+702,181
| +12% | +$50.4M |
2014 Q1
15 quarters
|
|
|
21
Aptiv
APTV
$7.98B
| $378M | 1.98% |
4,457,084
-5,754,782
| -56% | -$548M |
2013 Q2
18 quarters
|
|
22
Arrow Electronics
ARW
$10B
| $237M | 1.24% |
2,953,321
+17,217
| +0.6% | +$1.38M |
2013 Q2
18 quarters
|
|
|
23
American Express
AXP
$217B
| – | – |
-1,028,945
| Closed | -$93.1M | – |
|
|
24
Pediatrix Medical
MD
$2.46B
| – | – |
-2,491,731
| Closed | -$107M | – |
|
|
25
Progressive
PGR
$135B
| – | – |
-6,106,851
| Closed | -$296M | – |
|
Similar funds
EQF
Longview Partners's Q4 2017 Portfolio in Review
As of Q4 2017, Longview Partners held 25 positions worth $19.1B, up 3.2% from $18.5B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Longview Partners's Q4 2017 filing shows 21 increased, 1 reduced and 3 closed positions. The largest sale was Aptiv, an estimated $548M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 29% a quarter earlier, followed by Financials and Industrials.
- Longview Partners added most to Oracle in Q4 2017, an estimated $86.9M increase.
- Longview Partners's biggest Q4 2017 reduction was Aptiv, cutting an estimated $548M.
- Longview Partners fully exited Progressive in Q4 2017, selling an estimated $296M.
- Longview Partners's ten largest holdings make up 55% of its $19.1B portfolio in Q4 2017.
- Longview Partners opened 0 new positions and closed 3 in Q4 2017.
- Longview Partners's portfolio value rose 3.2% quarter-over-quarter to $19.1B.
Based on Longview Partners's 13F filing for Q4 2017, filed 6 Feb 2018.